A cross-sectional CT scan of a female
kidney cancer patient shows relatively little visceral fat (red) and more subcutaneous fat (blue).
Not exact matches
Recent studies have
shown a similar survival benefit for obese
patients with colorectal or
kidney cancer.
The multicenter trial involving 100
patients showed that the addition of ipilimumab to nivolumab, which is currently FDA - approved for treatment of
kidney cancer, leads to responses that can last beyond two years.
An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with results from a phase I trial
showing that, among 236
patients with various types of
cancer, the treatment shrank tumors in 28 percent of melanoma
patients, 30 percent of
patients with
kidney cancer, and 18 percent of
patients with advanced non-small cell lung
cancer.
While an earlier study had
shown a similar immunotherapy drug to be effective for a significant proportion of
patients with advanced melanoma or lung or
kidney cancer, checkpoint inhibitors weren't making headway with colon
cancer.
The FDA - approved drug nivolumab, or OPDIVO, has
shown up to a 25 percent response rate for
kidney cancer tumors, which means
patients» tumors shrink by 30 percent or more.
A new study
shows female
kidney cancer patients with limited visceral fat survive longer than those with larger fat deposits.